Importance Multiple myeloma is a hematologic malignancy characterized by presence of
abnormal clonal plasma cells in the bone marrow, with potential for uncontrolled growth …

Multiple myeloma (MM) is a plasma cell neoplasm that accounts for 2% of all haematological
malignancies and predominantly affects older individuals (with a median age at diagnosis of …

Abstract Disease Overview Multiple myeloma accounts for approximately 10% of
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …

PURPOSE Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous
outcomes, and approximately 60% of them are at intermediate-risk according to the Revised …

Since the publication of the article entitled “Multiple Myeloma: EHA-ESMO Clinical Practice
Guidelines for Diagnosis, Treatment and Follow-up”(HemaSphere. 2021; 5: e528) …

Multiple myeloma (MM) accounts for 1% of all cancers and $10% of all haematological
malignancies. The incidence in Europe is 4.5–6.0/100 000/year with a median age at …

Background Maintenance therapy following autologous stem cell transplantation (ASCT)
can delay disease progression and prolong survival in patients with multiple myeloma …

Abstract Gain of chromosome 1q (+ 1q) is one of the most common recurrent cytogenetic
abnormalities in multiple myeloma (MM), occurring in approximately 40% of newly …

Disease overview Multiple myeloma accounts for approximately 10% of hematologic
malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow plasma cells or …

Use of proteasome inhibitors (PIs) has been the therapeutic backbone of myeloma treatment
over the past decade. Many PIs are being developed and evaluated in the preclinical and …